World J Meta-Anal Jun 2026 peer-reviewed: ivermectin PAK1/YAP1/PD-L1 anti-cancer mechanisms confirmed. Anticancer Research Jun 2026: 197 patients, 48.4% tumour regression at 6 months. Complete guide: cancer-type mechanisms (breast/prostate/lung/colorectal/GBM), drug interaction table with chemo agents, active clinical trials, NCI honest position, and why treatment delay remains the greatest danger despite compelling signals.